SRI International has utilized their biosafety level 3 (BSL3) facilities and mobilized its virology and immunology groups to develop preclinical and in vitro COVID-19 models.

TORONTO (PRWEB) November 02, 2021

Given the enormity of the COVID-19 pandemic, researchers are pursuing multiple drug, immune therapy and vaccine development strategies. SRI, as one of NIHs leading preclinical partners, has a long history of rapid response to critical issues like COVID-19. To help address this new viral challenge, SRI International has utilized their biosafety level 3 (BSL3) facilities and mobilized its virology and immunology groups to develop preclinical and in vitro COVID-19 models.

Using these novel models, they have the ability to test novel antiviral approaches against multiple SARS-CoV-2 strains, including the Delta strain. For example, they can partner with a wide variety of companies to screen their novel biologics for activity against SARS-CoV-2 variants in their own in vitro assays. Within months of the pandemic, SRI scientists determined in vivo LD50 infection curves and used these parameters to best assess anti-viral compounds.

These assays can generate realistic data to guide the development of robust antiviral approaches to eliminate the pandemic threat. SRI is working with scientists from around the world to create practical antiviral treatments that will be used for years. Additionally, they are working to develop and validate rapid in vitro testing platforms to screen for SARS-CoV-2 exposure and infection.

Join Mary Lanier, PhD, Director of Immunology and Virology, SRI Biosciences, A Division of SRI International, in a live webinar on Thursday, November 18, 2021 at 1pm EST (10am PST) to hear more about these preclinical models including the data they have generated and how they are working with partners to improve preclinical modeling for COVID-19 therapeutics and vaccines.

For more information, or to register for this event, visit Rising to the COVID-19 Challenge: Using Preclinical Models to Assess Vaccines and Antivirals.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Continued here:
Rising to the COVID-19 Challenge: Using Preclinical Models to Assess Vaccines and Antivirals, Upcoming Webinar Hosted by Xtalks - PR Web